Xeligekimab Injection | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Company: Chongqing Genrix Biopharmaceutical Co., Ltd.
Medicine type: Biologic
Therapeutic area: Dermatology
Indications recorded in the public source: (1) Psoriasis: for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. (2) Ankylosing spondylitis (radiographic axial spondyloarthritis): for adults with an inadequate response to conventional treatment.
Indication source and scope: Source date(s): 2025, 2026. Indications transcribed from the public NHSA manufacturer submission; this is not verification of the complete current label.
Prescribing-information limitations: Complete official prescribing information obtained. Mainland China label. The full document is an older version; newer indications are supported by separate announcements or submissions.
China availability status: Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status: Market-by-market verification pending.
Insurance classification: Included in national insurance (Category B)
Insurance edition: 2025 edition; effective 1 January 2026
Insurance restrictions: Limited to: (1) adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy; (2) adults with ankylosing spondylitis (radiographic axial spondyloarthritis) with an inadequate response to conventional treatment.
Insurance period: 2026-01-01 to 2027-12-31
Insurance verification notes: Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.

Sources

Open the interactive record, public price references and discussions